Cv Sciences, INC 10-Q quarterly reports

CV Sciences, Inc. (CVSI) filed its Q2 2026 10-Q, revealing a 17.5% year-over-year revenue decline and a widening net loss, raising going concern doubts.

CV Sciences, Inc. reported a reduced net loss for Q3 and the first nine months of 2025, but faces significant challenges from new federal THC regulations and ongoing liquidity concerns.

CV Sciences, Inc. reported significantly reduced net and operating losses and positive cash flow from operations for the first half of 2025, despite a decline in product sales.

CV Sciences reports a decrease in net product sales for Q1 2025, alongside strategic cost reductions and ongoing efforts to secure additional funding.

CV Sciences reports a net loss for Q3 2024, with a slight decrease in revenue and ongoing efforts to manage costs and explore strategic opportunities.

CV Sciences reports a slight decrease in net product sales but improved gross margins in the second quarter of 2024, while also completing two strategic acquisitions.

CV Sciences reports a net loss for Q1 2024, despite improved gross margins, while also navigating strategic acquisitions and concerns about its ability to continue as a going concern.